OncoMatch/Clinical Trials/NCT07308717

Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol

Is NCT07308717 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies non-drug interventions for breast cancer.

Phase 4RecruitingMemorial Sloan Kettering Cancer CenterNCT07308717Data as of Jun 2026

This study aims to assess whether gabapentin should be a standard component of peri-operative pain control in mastectomy patients at Memorial Sloan Kettering Cancer Center.

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Demographics

Ages ≤ 65

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
Memorial Sloan Kettering Monmouth (Limited protocol activities) · Middletown, New Jersey
Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities) · Commack, New York
Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT07308717 currently recruiting?

Yes, this trial is currently recruiting patients.

Is there an age limit?

Yes. Patients must be 65 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify

Breast Carcinoma trials